MLYS Mineralys Therapeutics Inc

Price (delayed)

$24.99

Market cap

$2.06B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2

Enterprise value

$1.95B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 13

We are a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone ...

Highlights
MLYS's equity has surged by 87% year-on-year
The company's quick ratio has surged by 71% YoY

Key stats

What are the main financial stats of MLYS

MLYS stock price

How has the Mineralys Therapeutics stock price performed over time
Intraday
-0.28%
1 week
-20.77%
1 month
-15.72%
1 year
61.02%
YTD
-31.14%
QTD
-7.75%

Financial performance

How have Mineralys Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$171.5M
Net income
-$151.78M
Gross margin
N/A
Net margin
N/A
The net income is up by 19% year-on-year
The company's operating income rose by 15% YoY

Price vs fundamentals

How does MLYS's price correlate with its fundamentals

Growth

What is Mineralys Therapeutics's growth rate over time

Valuation

What is Mineralys Therapeutics stock price valuation
P/E
N/A
P/B
3.23
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 46% year-on-year and by 13% since the previous quarter
MLYS's equity has surged by 87% year-on-year
The stock's P/B is 15% less than its last 4 quarters average of 3.8

Efficiency

How efficient is Mineralys Therapeutics business performance
MLYS's ROIC has soared by 68% YoY and by 24% from the previous quarter
MLYS's ROE has soared by 61% YoY and by 15% QoQ
The ROA has soared by 59% year-on-year and by 15% since the previous quarter

Dividends

What is MLYS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MLYS.

Financial health

How did Mineralys Therapeutics financials performed over time
Mineralys Therapeutics's total assets has soared by 84% YoY
The company's quick ratio has surged by 71% YoY
Mineralys Therapeutics's debt is 100% lower than its equity
MLYS's equity has surged by 87% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.